Allergan, Inc. : AGN

All AGN Articles

189 Articles

Paul Ausick | Nov 17, 2016 at 12:50 PM EST

Hedge Funds Bought Apple, P&G in Q3; Dumped Allergan, Charter

Building on a turn toward more equity investments in the second quarter of this year, the top 50 hedge funds…

Lee Jackson | Nov 11, 2016 at 9:35 AM EST

Top Biotech and Health Care Stocks Set to Run on Huge Republican Sweep

With the Republicans now set to control both Congress and the White House, many on Wall Street feel that there…

Jon C. Ogg | Oct 31, 2016 at 8:50 AM EDT

Top Analyst Upgrades and Downgrades: AbbVie, Chevron, Home Depot, Nike, Qualcomm, VMware and More

The top analyst upgrades, downgrades and initiations seen on Monday morning include AbbVie, Chevron, Home Depot, Nike, Qualcomm and VMware.

Trey Thoelcke | Oct 21, 2016 at 7:45 AM EDT

Why Despite Alkermes Success, Suicidal Ideation Still Eludes Big Pharma

Alkermes' positive Phase 3 results for its novel antidepressant is serving as a rising tide — a storm surge even…

Chris Lange | Sep 20, 2016 at 11:25 AM EDT

Tobira Therapeutics Skyrockets on Allergan Acquisition

Tobira Therapeutics shares skyrocketed on Tuesday after Allergan announced that it will acquire the company.

Chris Lange | Sep 14, 2016 at 10:25 AM EDT

Vitae Shares Jump Over 150% on Allergan Acquisition

The goal of Allergan’s bid for Vitae Pharmaceuticals is to bolster its dermatology product pipeline, and Vitae shareholders appear happy…

Paul Ausick | Aug 22, 2016 at 7:55 AM EDT

Pfizer Pays a Big Premium for Medivation

In one of the longest running bidding wars in recent times, Pfizer has finally reeled in cancer-drug maker Medivation.

Jon C. Ogg | Aug 19, 2016 at 8:55 AM EDT

Top Analyst Upgrades and Downgrades: AK Steel, Allergan, ArcelorMittal, Symantec, Teck Resources, US Steel, Emerson, Hormel and More

The top analyst upgrades, downgrades and initiations seen on Friday morning include AK Steel, Allergan, ArcelorMittal, Symantec, Teck Resources, US…

Jon C. Ogg | Aug 15, 2016 at 1:05 PM EDT

Credit Suisse Issues Top Pharma Picks in Bull/Bear Upside Analysis

Credit Suisse has run bullish and bearish scenarios for what the firm feels is a reasonable upside and downside for…

Paul Ausick | Aug 8, 2016 at 7:55 AM EDT

Why Allergan Earnings Aren’t Telling the Whole Story

Allergan reported mixed second-quarter 2016 results and announced share buybacks before markets opened Monday morning.

Chris Lange | Aug 3, 2016 at 12:50 PM EDT

What Expect From Teva Earnings

Teva Pharmaceutical Industries is scheduled to release its second-quarter financial results before the markets open on Thursday.

Jon C. Ogg | Jul 25, 2016 at 8:40 AM EDT

Top Analyst Upgrades and Downgrades: Allergan, GE, HP Enterprise, Southwest Air, Williams Companies and More

The top analyst upgrades, downgrades and initiations seen on Monday morning include Allergan, General Electric, Hewlett Packard Enterprise, Southwest Airlines…

Trey Thoelcke | Jul 14, 2016 at 12:20 PM EDT

Why Teva’s $20 Billion Bond Sale Makes Sense, as Long as It’s a Fixed Rate

Lucky for Teva Pharmaceuticals, interest rates on all kinds of debt have never been lower in recorded human history, and…

Chris Lange | Jul 13, 2016 at 10:55 AM EDT

Why the Teva Acquisition Proves It Is a Stock to Own for the Decade

Even though the trend toward generic drugs is only likely to grow, the drug price pressures hanging over the sector…

Lee Jackson | Jun 24, 2016 at 8:56 AM EDT

J.P. Morgan Very Positive on 3 Battered Specialty Pharmaceutical Stocks

[cnxvideo id=”655379″ placement=”ros”]Ever since the infamous Hillary Clinton tweet about pharmaceutical drug pricing, the biotech and specialty pharmaceutical stocks have…

1 … 3 4 5 6 7 … 13

Allergan, Inc. : AGN

All AGN Articles

Hedge Funds Bought Apple, P&G in Q3; Dumped Allergan, Charter

Top Biotech and Health Care Stocks Set to Run on Huge Republican Sweep

Top Analyst Upgrades and Downgrades: AbbVie, Chevron, Home Depot, Nike, Qualcomm, VMware and More

Why Despite Alkermes Success, Suicidal Ideation Still Eludes Big Pharma

Tobira Therapeutics Skyrockets on Allergan Acquisition

Vitae Shares Jump Over 150% on Allergan Acquisition

Pfizer Pays a Big Premium for Medivation

Top Analyst Upgrades and Downgrades: AK Steel, Allergan, ArcelorMittal, Symantec, Teck Resources, US Steel, Emerson, Hormel and More

Credit Suisse Issues Top Pharma Picks in Bull/Bear Upside Analysis

Why Allergan Earnings Aren’t Telling the Whole Story

What Expect From Teva Earnings

Top Analyst Upgrades and Downgrades: Allergan, GE, HP Enterprise, Southwest Air, Williams Companies and More

Why Teva’s $20 Billion Bond Sale Makes Sense, as Long as It’s a Fixed Rate

Why the Teva Acquisition Proves It Is a Stock to Own for the Decade

J.P. Morgan Very Positive on 3 Battered Specialty Pharmaceutical Stocks

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

NVIDIA’s New Quantum‑AI Models Are Impressive — and the Market Doesn’t Seem Ready to Price the Step‑Change

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple's $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

Allergan, Inc. : AGN

All AGN Articles

Hedge Funds Bought Apple, P&G in Q3; Dumped Allergan, Charter

Top Biotech and Health Care Stocks Set to Run on Huge Republican Sweep

Top Analyst Upgrades and Downgrades: AbbVie, Chevron, Home Depot, Nike, Qualcomm, VMware and More

Why Despite Alkermes Success, Suicidal Ideation Still Eludes Big Pharma

Tobira Therapeutics Skyrockets on Allergan Acquisition

Vitae Shares Jump Over 150% on Allergan Acquisition

Pfizer Pays a Big Premium for Medivation

Top Analyst Upgrades and Downgrades: AK Steel, Allergan, ArcelorMittal, Symantec, Teck Resources, US Steel, Emerson, Hormel and More

Credit Suisse Issues Top Pharma Picks in Bull/Bear Upside Analysis

Why Allergan Earnings Aren’t Telling the Whole Story

What Expect From Teva Earnings

Top Analyst Upgrades and Downgrades: Allergan, GE, HP Enterprise, Southwest Air, Williams Companies and More

Why Teva’s $20 Billion Bond Sale Makes Sense, as Long as It’s a Fixed Rate

Why the Teva Acquisition Proves It Is a Stock to Own for the Decade

J.P. Morgan Very Positive on 3 Battered Specialty Pharmaceutical Stocks

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

NVIDIA’s New Quantum‑AI Models Are Impressive — and the Market Doesn’t Seem Ready to Price the Step‑Change

Featured Reads

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple's $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not